Susan Kelley

Susan L.
Kelley is currently Director at Deciphera Pharmaceuticals LLC since 2019, Independent Director at Daré Bioscience, Inc. since 2014, and Director at A2 Biotherapeutics, Inc. Former roles include Independent Director at ArQule, Inc. from 2011 to 2020, Independent Non-Executive Director at The Sustainable Nutrition Group Pty Ltd. from 2013 to 2015, Director at Audeo Oncology, Inc. in 2012, Independent Director at IDEAYA Biosciences, Inc. from 2021 to 2025, Independent Director at Cerulean Pharma, Inc. from 2014 to 2017, Executive Director-Oncology Clinical Research at Bristol-Myers Squibb World Wide Medicines Group from 1987 to 2001, Independent Non-Executive Director at Vascular Biogenics Ltd. from 2011 to 2020, Independent Director at Immune Design Corp.
from 2016 to 2019, Executive Director at Oncology Clinical Research & Development in 2001, Independent Director at Deciphera Pharmaceuticals, Inc. from 2019 to 2024, Vice President-Global Clinical Development at Bayer Pharma AG and Bayer HealthCare Pharmaceuticals, Inc. in 2008, Chief Medical Officer at Multiple Myeloma Research Consortium from 2008 to 2011, and Assistant Professor at Yale School of Medicine.
Education includes undergraduate degree from Colgate University and doctorate from Duke University School of Medicine.